



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, India.
Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Date: 08th February 2022

To
National Stock Exchange of India Limited &
BSE Limited.
Scrip Code: NSE- GRANULES; BSE-532482.

Sub: Outcome of 210th Board meeting dated 08th February 2022.
Ref: Regulation 30 and 33 of the Listing Regulations.

Dear Sir,

The Board of Directors at their meeting has -

1. Approved the Un-Audited financial results (Standalone & Consolidated) for the third quarter ended December 31, 2021, prepared under Indian Accounting Standards (Ind - AS).
2. Declared third interim dividend of 25 paise per share of face value of Re. 1/- each representing 25% of paid-up capital for the financial year 2021-22.
3. Fixed the record date as February 18, 2022, for the purpose of payment of third interim dividend for the financial year 2021-22.

Pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing the Un-Audited financial results (Standalone and Consolidated) of the Company for the third quarter ended December 31, 2021.

We also enclose a copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations and press release.

The meeting of the Board of Directors of the Company commenced at 10.00 A.M and concluded at 1.30 P.M.

Request you to take the above information on record.

Thanking You.
Yours faithfully,

For GRANULES INDIA LIMITED

T. Chaitanya
CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)

Encl: As above



B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited Review Report on unaudited standalone financial results of Granules India Limited for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Granules India Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Granules India Limited (“the Company”) for the quarter ended 31 December 2021 and year-to-date results for the period from 1 April 2021 to 31 December 2021 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP**
Chartered Accountants

Firm’s Registration No.: 116231W/W-100024

SULABH
KUMAR KEDIA

Digitally signed by
SULABH KUMAR KEDIA
Date: 2022.02.08
13:26:18 +05'30'

Sulabh Kumar Kedia
Partner

Membership No.: 066380
UDIN:22066380AATUZH7260

Hyderabad
08 February 2022

Registered Office:

Statement of Standalone Unaudited Results for the quarter and nine months ended December 31, 2021

Sl No.	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
	Income						
1	Revenue from operations	88,977.85	70,369.40	77,601.12	232,558.84	235,343.12	313,498.24
2	Other income	478.52	428.32	294.92	1,323.09	1,066.22	1,372.32
3	Total income (1+2)	89,456.37	70,797.72	77,896.04	233,881.93	236,409.34	314,870.56
4	Expenses						
	(a) Cost of materials consumed	51,347.43	41,481.92	39,060.41	136,080.67	114,872.70	150,219.35
	(b) Changes in inventories of work in progress and finished goods	(2,623.62)	(2,128.56)	364.08	(8,910.30)	(698.53)	744.93
	(c) Employee benefits expense	7,183.95	6,429.44	7,570.25	20,734.85	24,078.58	31,825.23
	(d) Finance costs	295.59	401.17	594.22	1,235.14	1,802.13	2,377.39
	(e) Depreciation and amortisation expense	3,112.67	3,185.57	2,977.04	9,447.81	8,794.03	11,845.14
	(f) Other expenses	13,866.21	15,245.30	10,469.62	40,785.59	33,244.65	44,571.50
	Total expenses	73,182.23	64,614.84	61,035.62	199,373.76	182,093.56	241,583.54
5	Profit before tax (3-4)	16,274.14	6,182.88	16,860.42	34,508.17	54,315.78	73,287.02
6	Tax expense						
	a) Current tax	4,212.86	1,600.55	4,369.58	8,933.07	15,549.89	20,231.19
	b) Deferred tax	(71.66)	(27.23)	(89.60)	(151.96)	(1,761.94)	(1,697.38)
	c) Adjustment of tax relating to earlier periods	-	-	(525.10)	-	(525.10)	(525.10)
	Total tax expense	4,141.20	1,573.32	3,754.88	8,781.11	13,262.85	18,008.71
7	Profit for the period (5-6)	12,132.94	4,609.56	13,105.54	25,727.06	41,052.93	55,278.31
8	Other comprehensive income (net of tax)						
	(a) (i) items that will not be reclassified to profit or loss	-	-	-	-	-	(36.69)
	(ii) income tax on (i) above	-	-	-	-	-	9.23
	(b) (i) items that will be reclassified to profit or loss	500.51	1,769.84	(1,789.48)	1,189.30	(3,403.76)	(699.98)
	(ii) income tax on (i) above	(125.97)	(445.43)	450.38	(299.32)	856.67	176.17
	Total other comprehensive income, net of tax	374.54	1,324.41	(1,339.10)	889.98	(2,547.09)	(551.27)
9	Total comprehensive income (7+8)	12,507.48	5,933.97	11,766.44	26,617.04	38,505.84	54,727.04
10	Paid-up equity share capital (Face Value of Rs.1/- per share)	2,480.06	2,476.75	2,476.75	2,480.06	2,476.75	2,476.75
11	Other equity						213,785.42
12	Earnings per share (Face value Rs. 1/- each)						
	(a) Basic (in Rs.)	4.89	1.86	5.29	10.38	16.44	22.18
	(b) Diluted (in Rs.)	4.88	1.85	5.26	10.34	16.37	22.09
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

Notes:

- The above standalone un-audited financial results for the quarter and nine months ended December 31, 2021 have been reviewed by the Audit Committee on February 08, 2022 and approved by the Board of Directors at their meeting held on February 08, 2022.
- The standalone un-audited financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Auditors of the Company have carried out Limited Review of the financial results for the quarter and nine months ended December 31, 2021.
- During the quarter ended December 31, 2021, the Company has recognised duty drawback claims of Rs 1,725.31 lakhs pertaining to the period prior to April 1, 2021, for purchases made from suppliers in Domestic Tariff Area by its Export Oriented Units. These claims were recognized, in accordance with Ind AS 37 – "Provisions, Contingent Liabilities and Contingent Assets", as it has become virtually certain that the claim will be realized by the Company.
- As the COVID-19 out-break continues to evolve, the Company continues to closely monitor any material changes to future economic conditions. Based on the assessment done by the management of the Company, there is no significant / material impact of COVID-19 on the results for the quarter and nine months ended December 31, 2021 and year ended March 31, 2021. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Company will continue to monitor any material changes to future economic conditions.
- The Company operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- The Board of Directors at their meeting held on February 08, 2022 has declared third interim dividend of 0.25 paise per equity share of Re.1/- each.
- The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the code becomes effective.
- On March 24, 2021, the Ministry of Corporate Affairs (MCA) through notification, amended Schedule III to the Companies Act, 2013, applicable for financial period commencing from April 01, 2021. The Company has incorporated the changes as per the said amendment in the above results and has also changed comparative numbers wherever it is applicable.
- The figures for the corresponding previous periods have been regrouped wherever necessary, to make them comparable.

for and on behalf of the Board



 Dr. Krishna Prasad Chigurupati
 Chairman and Managing Director

 Place : Hyderabad
 Date : February 08, 2022


B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited Review Report on unaudited consolidated financial results of Granules India Limited for the quarter ended 31 December 2021 and year-to-date results for the period from 1 April 2021 to 31 December 2021 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Granules India Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Granules India Limited (“the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 31 December 2021 and year-to-date results for the period from 1 April 2021 to 31 December 2021 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
 - a. Granules USA Inc.
 - b. Granules Pharmaceuticals Inc.
 - c. Granules Europe Limited
 - d. Granules Life Sciences Private Limited
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Registered Office:

B S R & Associates LLP

6. We did not review the interim financial results of 2 Subsidiaries included in the Statement, whose interim financial results reflects total revenues of Rs. 36,200.34 lakhs and Rs. 106,135.09 lakhs, total net profit / (loss) after tax of Rs. (187.97) lakhs and Rs. 3,543.89 lakhs and total comprehensive income of Rs. 118.24 lakhs and Rs 4,820.95 lakhs, for the quarter ended 31 December 2021 and for the period from 1 April 2021 to 31 December 2021 respectively, as considered in the unaudited consolidated financial results. These interim financial results have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial results of 2 Subsidiaries which have not been reviewed, whose interim financial results reflects total revenues of Rs . NIL and Rs. Nil, total net loss after tax of Rs. 58.13 lakhs and Rs. 143.49 lakhs and total comprehensive loss of Rs. 67.90 lakhs and Rs. 140.75 lakhs, for the quarter ended 31 December 2021 and for the period from 1 April 2021 to 31 December 2021 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Associates LLP**
Chartered Accountants
Firm's Registration No.:116231W/W-100024

SULABH
KUMAR KEDIA

Digitally signed by
SULABH KUMAR KEDIA
Date: 2022.02.08
13:25:33 +05'30'

Sulabh Kumar Kedia
Partner

Membership No.: 066380
UDIN:22066380AATWBI4351

Hyderabad
08 February 2022



Rs in lakhs

Statement of Consolidated Unaudited Results for the quarter and nine months ended December 31, 2021


Sl No.	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
	Income						
1	Revenue from operations	99,676.99	88,833.09	84,451.15	273,494.74	243,822.95	323,754.28
2	Other income	486.77	435.21	1,641.31	1,364.73	2,360.35	2,688.18
3	Total income (1+2)	100,163.76	89,268.30	86,092.46	274,859.47	246,183.30	326,442.46
	Expenses						
	(a) Cost of materials consumed	56,004.91	46,046.20	41,361.23	148,057.48	120,523.20	159,027.67
	(b) Changes in inventories of work in progress and finished goods	(2,812.20)	(2,387.48)	(2,260.76)	(12,298.75)	(15,552.11)	(19,900.33)
	(c) Employee benefits expense	10,531.45	9,251.61	10,096.12	29,322.02	30,830.20	40,818.10
	(d) Finance costs	459.30	546.30	724.42	1,684.92	1,946.61	2,628.41
	(e) Depreciation and amortisation expense	3,922.92	3,984.09	3,684.61	11,845.15	10,698.44	15,146.25
	(f) Other expenses	18,579.39	20,804.67	14,098.46	55,460.53	42,699.44	58,285.93
	Total expenses	86,685.77	78,245.39	67,704.08	234,071.35	191,145.78	256,006.03
5	Profit before tax (3-4)	13,477.99	11,022.91	18,388.38	40,788.12	55,037.52	70,436.43
	Tax expense						
	a) Current tax	4,278.89	1,840.65	4,956.47	9,573.42	17,055.09	20,255.74
	b) Deferred tax	(888.96)	1,114.39	(530.29)	1,038.58	(3,488.08)	(4,046.68)
	c) Adjustment of tax relating to earlier periods	-	-	(718.53)	-	(718.53)	(718.53)
	Total tax expense	3,389.93	2,955.04	3,707.65	10,612.00	12,848.48	15,490.53
7	Profit for the period (5-6)	10,088.06	8,067.87	14,680.73	30,176.12	42,189.04	54,945.90
	Other comprehensive income (net of tax)						
	(a) (i) items that will not be reclassified to profit or loss	-	-	-	-	-	(36.69)
	(ii) income tax on (i) above	-	-	-	-	-	9.23
	(b) (i) items that will be reclassified to profit or loss	796.95	1,668.15	(2,525.39)	2,469.10	(5,559.98)	(2,764.76)
	(ii) income tax on (i) above	(125.97)	(445.43)	450.38	(299.32)	856.67	176.17
	Total other comprehensive income, net of tax	670.98	1,222.72	(2,075.01)	2,169.78	(4,703.31)	(2,616.05)
9	Total comprehensive income (7+8)	10,759.04	9,290.59	12,605.72	32,345.90	37,485.73	52,329.85
10	Paid-up equity share capital (Face Value of Rs. 1/- per share)	2,480.06	2,476.75	2,476.75	2,480.06	2,476.75	2,476.75
11	Other equity						214,850.68
12	Earnings per share (Face value Rs. 1/- each)						
	(a) Basic (in Rs.)	4.07	3.26	5.92	12.18	16.90	22.05
	(b) Diluted (in Rs.)	4.05	3.24	5.90	12.12	16.82	21.95
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

Notes:

- The above consolidated un-audited financial results for the quarter and nine months ended December 31, 2021 have been reviewed by the Audit Committee on February 08, 2022 and approved by the Board of Directors at their meeting held on February 08, 2022.
- The consolidated un-audited financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Auditors of the Company have carried out Limited Review of the financial results for the quarter and nine months ended December 31, 2021.
- The subsidiaries considered for the consolidated financial statements for the quarter and nine months ended December 31, 2021 are Granules USA Inc., Granules Pharmaceuticals Inc., Granules Europe Limited and Granules Life Sciences Private Limited (together known as "Subsidiaries").
- The Group operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- During the quarter ended December 31, 2021, the Group has recognised duty drawback claims of Rs 1,725.31 lakhs pertaining to the period prior to April 1, 2021, for purchases made from suppliers in Domestic Tariff Area by its Export Oriented Units. These claims were recognized, in accordance with Ind AS 37 - "Provisions, Contingent Liabilities and Contingent Assets", as it has become virtually certain that the claim will be realized by the Company.
- As the COVID-19 out-break continues to evolve, the Group continues to closely monitor any material changes to future economic conditions. Based on the assessment done by the management of the Group, there is no significant / material impact of COVID-19 on the results for the quarter and nine months ended December 31, 2021 and year ended March 31, 2021. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Group will continue to monitor any material changes to future economic conditions.
- The Board of Directors at their meeting held on February 08, 2022 has declared third interim dividend of 0.25 paise per equity share of Re. 1/- each.
- The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the code will come into effect has not been notified. The Group will assess the impact of the Code when it comes into effect and will record any related impact in the period the code becomes effective.
- On March 24, 2021, the Ministry of Corporate Affairs (MCA) through notification, amended Schedule III to the Companies Act, 2013, applicable for financial period commencing from April 01, 2021. The Group has incorporated the changes as per the said amendment in the above results and has also changed comparative numbers wherever it is applicable.
- The figures for the corresponding previous periods have been regrouped wherever necessary, to make them comparable.
- Standalone results for the quarter / year ended are as under -

Particulars	Rs in lakhs					
	Quarter ended			Nine months ended		Year ended
	31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
Revenue from Operations	88,977.85	70,369.40	77,601.12	232,558.84	235,343.12	313,498.24
Profit Before Tax	16,274.14	6,182.88	16,860.42	34,508.17	54,315.78	73,287.02
Profit After Tax	12,132.94	4,609.56	13,105.54	25,727.06	41,052.93	55,278.31

for and on behalf of the Board


 Hyderabad
 Dr. Krishna Prasad Chigurupati
 Chairman and Managing Director

Place : Hyderabad
 Date : February 08, 2022



Granules India reports Income from operations at INR 997 Cr up 18% YoY, EBITDA at INR 174 Cr, EBITDA Margin at 17%; PAT at INR 101 Cr.

Hyderabad, India, February 8, 2022: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter and nine months ended December 31, 2021.

Financial Highlights (All numbers in INR Cr., except Margins)


CONSOLIDATED FINANCIALS	Q3FY22	Q3FY21	Growth (YoY)
Income from Operations	997	845	18%
Operating Profit	174	212	(18%)
Operating Profit Margin	17%	25%	
PAT	101	147	(31%)
Net Profit Margin	10%	17%	

Financial and Business Highlights for Q3FY22

- Revenue for Q3FY22 stood at INR 997 Crs, growth of 18% YoY.
- FD segment grew by 8%, PFI grew by 32% and API 24% when compared to YoY.
- Increase in Paracetamol across all the segments by INR 108 Cr and increase in other molecules by INR 56 Crs in view of steady market capture by newly launched molecules.
- For the consecutive two quarters, revenue share of other molecules maintained at 19%.
- Revenue from Europe increased to 24.5% when compared to 18.6% YoY on account of increase in selling prices for Paracetamol.
- The overall gross margin recorded is lower in % terms due to change in Segment mix in the total revenue. Share of Finished dosage has come down from 57% in Q2 to 46% in Q3 due to higher inventory build-up at USA and year end.
- EBITDA stood at INR 174 Crs, down by 17.9% YoY. EBITDA margins stood at 17.4% compared to 25.1%. PAT at INR 101 Cr, down by 31.3%, driven by reduction in Gross margin and increase in Freight cost by INR 29 Crs on account of shortage of containers and increase in R&D cost by INR 13 Crs as part of our future growth strategy.
- During the quarter we filed two ANDA, two Canadian Dossiers, one US DMF, one CEP and received three ANDA approvals.
- The Board of Directors has declared its third interim dividend of 25 paise per equity share of INR 1/- each.

Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “I am pleased to share that we are slowly getting back to the normal as is evident from the revenue growth which came in despite the continuing disruptions and challenging environment such as raw material price increase, unstable supply from China and PAP supply constraints. We expect the situation to improve in coming quarters and remain focused on execution and agile to the market opportunities. We at Granules are now ready to take a leap to transform our business to the next level. We are strengthening management capabilities and are investing in R&D infrastructure, scientific talent, and partnerships in science & technology which will lead to sustainability, leadership, backward integration and focus on quality of our portfolio. Our initiatives will bring in the triple bottom line in the form of social, environmental, and financial advantages resulting in a greater stakeholder’s value.”

Segmental, Molecule and Geographical Mix for Q3 FY22 (All numbers in INR Cr)



About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 75+ countries with offices across India, US and UK. The Company has 7 manufacturing facilities out of which 6 are in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Contacts:

Krishna Raghunathan
040-69043573
VP – Finance and Investor Relations
krishna.raghunathan@granulesindia.com

Chaitanya Tummala
040-69043614
Company Secretary
chaitanya.tummala@granulesindia.com

Safe Harbor

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.